[{"indications": "Indications\u00a0pulmonary arterial hypertension; systemic sclerosis with ongoing\r\ndigital ulcer disease (to reduce number of new digital ulcers)", "name": "BOSENTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.1 Vasodilator antihypertensive drugs", "BOSENTAN"], "cautions": "Cautions\u00a0not to be initiated if systemic systolic\r\nblood pressure is below 85\u00a0mmHg; monitor\r\nhaemoglobin before and during treatment (monthly for first 4 months,\r\nthen 3-monthly); avoid abrupt withdrawal; monitor liver function before treatment, at monthly\r\nintervals during treatment, and 2 weeks after dose increase (reduce\r\ndose or suspend treatment if liver enzymes raised significantly)\u2014discontinue\r\nif symptoms of liver impairment; interactions: Appendix 1 (bosentan)", "side-effects": "Side-effects\u00a0diarrhoea, gastro-oesophageal reflux, flushing,\r\nhypotension, palpitation, oedema, syncope, headache, anaemia; less commonly thrombocytopenia, neutropenia; leucopenia; rarely liver cirrhosis, liver failure (see cautions above)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119711.htm", "doses": ["Pulmonary arterial hypertension, initially 62.5\u00a0mg twice\r\ndaily increased after 4 weeks to 125\u00a0mg twice daily; max. 250\u00a0mg twice\r\ndaily; child under 18 years see BNF for Children", "Systemic sclerosis with ongoing digital ulcer disease, initially\r\n62.5\u00a0mg twice daily increased after 4 weeks to 125\u00a0mg twice daily"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic in animal studies);\r\neffective contraception required during administration (hormonal contraception\r\nnot considered effective); monthly pregnancy tests advised"}]